NASDAQ:CLSD

Clearside Biomedical Stock Forecast, Price & News

$3.88
+0.86 (+28.48 %)
(As of 06/15/2021 12:04 PM ET)
Add
Compare
Today's Range
$3.62
$5.71
50-Day Range
$2.32
$3.19
52-Week Range
$1.25
$4.53
Volume913,952 shs
Average Volume172,793 shs
Market Capitalization$223.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37
30 days | 90 days | 365 days | Advanced Chart
Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.


Clearside Biomedical logo

About Clearside Biomedical

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.21 out of 5 stars

Medical Sector

942nd out of 2,100 stocks

Pharmaceutical Preparations Industry

462nd out of 832 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

Is Clearside Biomedical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical
or view top-rated stocks.

What stocks does MarketBeat like better than Clearside Biomedical?

Wall Street analysts have given Clearside Biomedical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clearside Biomedical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Clearside Biomedical
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings data on Sunday, May, 16th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. Clearside Biomedical had a negative trailing twelve-month return on equity of 220.12% and a negative net margin of 591.23%.
View Clearside Biomedical's earnings history
.

How has Clearside Biomedical's stock price been impacted by COVID-19 (Coronavirus)?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLSD shares have increased by 62.5% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CLSD?

3 analysts have issued 1-year target prices for Clearside Biomedical's stock. Their forecasts range from $6.00 to $9.00. On average, they expect Clearside Biomedical's share price to reach $7.50 in the next year. This suggests a possible upside of 78.1% from the stock's current price.
View analysts' price targets for Clearside Biomedical
or view top-rated stocks among Wall Street analysts.

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharm.D., Pharma.D., J.D., Pres, CEO & Director (Age 69, Pay $681.67k)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 57, Pay $430.33k)
  • Dr. Thomas A. Ciulla M.B.A., M.D., Chief Medical Officer & Chief Devel. Officer
  • Ms. Jenny R. Kobin, Head of Investor Relations (Age 54)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 52)
  • Mr. Rick McElheny, VP of Corp. Devel.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (7.31%), Acuta Capital Partners LLC (2.80%), BlackRock Inc. (1.52%), Renaissance Technologies LLC (0.98%), Geode Capital Management LLC (0.63%) and Morgan Stanley (0.62%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson and William D Humphries.
View institutional ownership trends for Clearside Biomedical
.

Which institutional investors are buying Clearside Biomedical stock?

CLSD stock was bought by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Morgan Stanley, RTW Investments LP, Assenagon Asset Management S.A., Millennium Management LLC, QS Investors LLC, BlackRock Inc., and Renaissance Technologies LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Nancy J Hutson, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical
or or view top insider-buying stocks.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $4.21.

How much money does Clearside Biomedical make?

Clearside Biomedical has a market capitalization of $242.41 million and generates $7.89 million in revenue each year. The company earns $-18,210,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Clearside Biomedical have?

Clearside Biomedical employs 33 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

Where are Clearside Biomedical's headquarters?

Clearside Biomedical is headquartered at 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.